Scarica l'app Stockscreener
226.08
1.15%
-2.63
Dopo l'orario di chiusura:
226.44
0.36
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$228.71
Aprire:
$228.93
Volume 24 ore:
3.94M
Relative Volume:
0.67
Capitalizzazione di mercato:
$399.57B
Reddito:
$59.64B
Utile/perdita netta:
$2.36B
Rapporto P/E:
170.59
EPS:
1.3253
Flusso di cassa netto:
$19.68B
1 W Prestazione:
-0.71%
1M Prestazione:
+4.29%
6M Prestazione:
+20.60%
1 anno Prestazione:
+28.33%
Intervallo 1D:
$225.05
$229.25
Intervallo di 1 settimana:
$223.11
$230.94
Portata 52W:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer - PR Newswire
Is AbbVie Inc. (4AB) stock undervalued after correctionWeekly Trade Summary & Community Consensus Picks - Newser
How Strong Is AbbVie's Immunology Franchise After Humira's LOE? - The Globe and Mail
Could buying AbbVie today set you up for life? - MSN
Could Buying AbbVie Today Set You Up for Life? - Nasdaq
Dry Eye Disease Treatment Market Outlook Report 2032 | Alcon - openPR.com
3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026 - The Motley Fool
Why AbbVie Inc. stock attracts global investorsMarket Performance Summary & Fast Exit and Entry Strategy Plans - Newser
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts - ts2.tech
Assessing AbbVie’s (ABBV) Valuation After New Cancer Data, EPKINLY Approval, and Dividend Hike - simplywall.st
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Dermal Fillers Market Size Report 2032 | AbbVie Inc., Galderma, - openPR.com
AbbVie looks to expand use cases for migraine drug after promising study - Crain's Chicago Business
Invesco Ltd. Lowers Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. stock undervalued at current priceSwing Trade & Weekly High Conviction Ideas - Newser
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook - ts2.tech
Metastatic Non-Small Cell Lung Cancer Market on Track for Major Expansion by 2034, According to DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - simplywall.st
AbbVie to feature new data at ASH 2025 - MarketScreener
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers - Investing News Network
AbbVie (NYSE: ABBV) highlights ASH 2025 advances in T-cell engagers, BCL-2 and ADCs - Stock Titan
2 Top Dividend Stocks to Buy Now and Hold For a Decade - AOL.com
Portfolio Design Labs LLC Has $571,000 Stake in AbbVie Inc. $ABBV - MarketBeat
Shelton Capital Management Has $7.29 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Loomis Sayles & Co. L P Purchases 18,866 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Fisher Asset Management LLC - MarketBeat
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
Willis Johnson & Associates Inc. Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Sepio Capital LP Has $38.93 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating - Seeking Alpha
AbbVie Inc. $ABBV is Distillate Capital Partners LLC's 4th Largest Position - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Everstar Asset Management LLC - MarketBeat
Edgestream Partners L.P. Takes $12.43 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress - PR Newswire
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets - ts2.tech
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73 - Yahoo Finance
AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength - ts2.tech
Aug Final Week: How cyclical is AbbVie Inc. stock compared to rivalsDip Buying & Capital Efficiency Focused Strategies - moha.gov.vn
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years - Finviz
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate - ts2.tech
Total liabilities & shareholders' equities of AbbVie, Inc. – SIX:ABBV - TradingView
Assessing AbbVie’s (ABBV) Valuation: Is There More Upside After Recent Performance? - Yahoo Finance
ABBVAbbvie Inc Stock Price and Quote - Finviz
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
AbbVie (ABBV) Gains Canadian Support for Ulcerative Colitis Trea - GuruFocus
AbbVie Announces Positive Reimbursement Recommendations for SKYRIZI® in Ulcerative Colitis by Canada's Drug Agency - Quiver Quantitative
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - MarketScreener
3 Dividend-Paying Stocks that Are Up Over 30% in 2025 - Tokenist
AbbVie Unit Fails To Revive Dermal Filler Patent On Appeal - Law360
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):